73,704 results match your criteria Hematopoietic Stem Cell Transplantation


Kinetics of disappearance and appearance of isoagglutinins A and B after ABO-incompatible hematopoietic stem cell transplantation.

Bone Marrow Transplant 2022 Jun 25. Epub 2022 Jun 25.

Diagnostic Department, University Hospital of Geneva, Geneva, Switzerland.

ABO-incompatible allogeneic hematopoietic stem cell transplantation (HSCT) can be complicated by poor red cell engraftment and hemolysis, both mediated by isoagglutinins. Anecdotally, isoagglutinins indicates an activation of donor's immunity or even relapse. Consequently, the routine monitoring of isoagglutinins could help physicians to predict the risk of complications. Read More

View Article and Full-Text PDF

SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies.

Blood Rev 2022 Jun 12:100984. Epub 2022 Jun 12.

Division of Infectious Disease, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, United States of America.

Individuals with hematological malignancies and hematopoietic stem cell transplant (HCT) recipients are immunologically heterogenous groups with varying degrees of immunosuppression at increased risk of severe disease and mortality from SARS-CoV-2 infection. SARS-CoV-2 vaccines are key interventions to preventing severe COVID-19 and its complications. While these individuals were excluded from initial vaccine trials, there is now a growing body of acceptable safety and immunogenicity data among these individuals. Read More

View Article and Full-Text PDF

Current state of antimicrobial stewardship in organ transplantation in Singapore.

Transpl Infect Dis 2022 Jun 25. Epub 2022 Jun 25.

Department of Infectious Diseases, Singapore General Hospital.

Background: Antibiotic stewardship programs (ASPs) are well established in the public hospitals in Singapore, but they are not mandatory for transplant programs. Given the positive impact of ASPs in non-organ transplant patients (improved use of broad-spectrum antibiotics, reduced length of stay and lower healthcare costs), stewardship principles are likely to benefit transplant recipients.

Methods: We reviewed the progress made in ASPs in the Asia Pacific region as well as the progress of our ASP over the last decade since it was established. Read More

View Article and Full-Text PDF

A 'waste product' to save the day in the field of transplantation: the evolving potential of extracellular vesicles.

Immunology 2022 Jun 25. Epub 2022 Jun 25.

Cell and Gene Therapy Laboratory, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

Graft rejection and graft-versus-host disease constitute the leading causes of morbidity and early mortality after solid organ and hematopoietic stem cell transplantation, respectively. Despite the current advances in immunotherapy, their incidence remains significant, underlying the need for new therapies to be developed. Extracellular vesicles (EV), and particularly small EV (sEV), have emerged as significant mediators of intercellular communication and immune modulation. Read More

View Article and Full-Text PDF

MAVS Expression in Alveolar Macrophages Is Essential for Host Resistance against .

J Immunol 2022 Jun 24. Epub 2022 Jun 24.

Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH;

Our recent data demonstrate a critical role of the RIG-I-like receptor family in regulating antifungal immunity against in a murine model. However, the importance of this pathway in humans and the cell types that use this innate immune receptor family to detect remain unresolved. In this study, using patients who underwent hematopoietic stem cell transplantation, we demonstrate that a polymorphism in human present in the donor genome was associated with the incidence of invasive pulmonary aspergillosis. Read More

View Article and Full-Text PDF

High Dose (Conditioning) Regimens used prior to Autologous Stem Cell Transplantation in Multiple Myeloma.

Transplant Cell Ther 2022 Jun 21. Epub 2022 Jun 21.

Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas. Electronic address:

The use of autologous stem cell transplantation (ASCT) in multiple myeloma (MM) is the standard of care in patients who are deemed transplant eligible. Novel therapies, namely immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, have revolutionized the treatment algorithm for MM but have not yet resulted in a cure. To achieve long-lasting disease control in MM, high-dose conditioning regimen followed by ASCT continues to be an essential part of the management of transplant-eligible patients with MM. Read More

View Article and Full-Text PDF

Treatments of Ph-like acute lymphoblastic leukemia: a real-world retrospective analysis from a single large center in China.

Leuk Lymphoma 2022 Jun 24:1-11. Epub 2022 Jun 24.

Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Collaborative Innovation Center of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Soochow University, Suzhou, P.R. China.

Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk subtype of ALL. We retrospectively studied 70 cases with Ph-like ALL and here present the largest study of CAR-T cell treatment and haplo-HSCT for this leukemia. Median age was 26 years and median leukocyte count was 31. Read More

View Article and Full-Text PDF

Acute gastrointestinal graft-versus-host disease with CMV and EBV superinfection in a patient with COVID-19.

Rev Esp Enferm Dig 2022 Jun 24. Epub 2022 Jun 24.

Gastroenterology , Centro Hospitalar Universitário de São João, Portugal.

A 60-year-old female was diagnosed with acute myeloid leukemia. After initial remission with chemotherapy, she relapsed and underwent allogeneic hematopoietic stem cell transplantation (HSCT). Two months later, she presented to emergency department with watery diarrhea, abdominal pain and fever. Read More

View Article and Full-Text PDF

Intravenous AsO as a promising treatment for psoriasis - an experimental study in psoriasis-like mouse model.

Immunopharmacol Immunotoxicol 2022 Jun 24:1-46. Epub 2022 Jun 24.

Department of Environmental Health and Toxicology, School of Public Health, Dalian Medical University, Dalian, Liaoning, China 116044.

Objective: To evaluate the efficacy and mechanistic bases of the intravenous injection of arsenic trioxide at clinical-relevant doses for treating imiquimod-induced psoriasis-like mouse model.

Methods: After inducing psoriasis-like skin lesions on the back of mice with imiquimod, mice in each group were injected with a clinical dose of arsenic trioxide through the tail vein. The changes in the gene expression, protein expression and distribution of relevant inflammatory factors were evaluated in the inflicted skin area, for mechanisms underlying the efficacy of intravenous AsO intervention. Read More

View Article and Full-Text PDF

Orbital myeloid sarcoma treated with low-dose venetoclax and a potent cytochrome P450 inhibitor.

J Oncol Pharm Pract 2022 Jun 23:10781552221110826. Epub 2022 Jun 23.

103564Facultad de Medicina y Hospital Universitario "Dr José Eleuterio González" Haematology service, Universidad Autónoma de Nuevo León, Monterrey, Mexico.

Case Report: We report the first case of orbital myeloid sarcoma that was successfully treated with a standard venetoclax dose of 25%. A 38-year-old man with acute myeloid leukemia (AML) post-haplo-hematopoietic stem cell transplantation (HSCT) presented with a nine-month history of progressive right proptosis and a visual acuity deficit. The patient was treated with venetoclax (100 mg orally on days 1-28), cytarabine (40 mg subcutaneously, days 1-10), and itraconazole (100 mg twice daily orally on days 1-28). Read More

View Article and Full-Text PDF

Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease.

Indian J Hematol Blood Transfus 2022 Jul 7;38(3):601-605. Epub 2022 Feb 7.

Ankara University School of Medicine, Hematology Department, Ankara, Turkey.

Steroid-refractory acute graft-versus-host disease (SR-aGVHD) treatment has a low response rate and a high risk of infection in allogeneic hematopoietic stem cell transplantation. The standard approach to be applied in this situation is uncertain. This study aims to evaluate the effectiveness and safety of alpha-1-antitrypsin (AAT). Read More

View Article and Full-Text PDF

Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors.

Ther Adv Hematol 2022 17;13:20406207221090882. Epub 2022 Jun 17.

Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Introduction: Azacitidine (AZA) either single-agent or with donor lymphocytes infusions (DLI) has been used as a salvage treatment for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) relapsing after allogeneic hematopoietic stem cell transplantation (HSCT). To date, the majority of data come from patients relapsed after HSCT from full-matched donors.

Methods: We report a multicenter, collaborative, retrospective analysis of 71 patients with hematologic ( = 40, 56%) and molecular relapse ( = 31, 44%) of myeloid neoplasms after HSCT from alternative donors (mismatched unrelated,  = 39, 55%; haploidentical,  = 29, 41%) consecutively treated at three European centers with AZA ± DLI. Read More

View Article and Full-Text PDF

Case Report: Langerhans Cell Sarcoma With Intracranial and Extracranial Communication on the Left Frontal Bone.

Front Surg 2022 7;9:882694. Epub 2022 Jun 7.

Department of Neurosurgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.

Background: Langerhans cell sarcoma (LCS) is an extremely rare type of malignant tumor that originates from Langerhans cells (LC). It is characterized by the malignant proliferation and dissemination of LC and is extremely invasive, with rapid progression and a poor prognosis. Treatment includes resection of lesions, radiotherapy, chemotherapy, immunotherapy, and transplantation of hematopoietic stem cells. Read More

View Article and Full-Text PDF

Cellular and Humoral Immunity after the Third Vaccination against SARS-CoV-2 in Hematopoietic Stem-Cell Transplant Recipients.

Vaccines (Basel) 2022 Jun 18;10(6). Epub 2022 Jun 18.

Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.

Protecting vulnerable groups from severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection is mandatory. Immune responses after a third vaccination against SARS-CoV-2 are insufficiently studied in patients after hematopoietic stem-cell transplantation (HSCT). We analyzed immune responses before and after a third vaccination in HSCT patients and healthy controls. Read More

View Article and Full-Text PDF

Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation.

Pharmaceutics 2022 May 27;14(6). Epub 2022 May 27.

Hospital Pharmacy, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.

For patients with myelofibrosis, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment to date. Busulfan-based conditioning regimens are commonly used, although high inter-individual variability (IIV) in busulfan drug exposure makes individual dose selection challenging. Since data regarding the IIV in patients with myelofibrosis are sparse, this study aimed to develop a population pharmacokinetic (PopPK) model of busulfan and its metabolite sulfolane in patients with myelofibrosis. Read More

View Article and Full-Text PDF

Nocardia Infections in the Immunocompromised Host: A Case Series and Literature Review.

Microorganisms 2022 May 29;10(6). Epub 2022 May 29.

Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milano, Italy.

Nocardia is primarily considered an opportunistic pathogen and affects patients with impaired immune systems, solid-organ transplant recipients (SOTRs), and patients with haematologic malignancies. We present the cases of six patients diagnosed with nocardiosis at our center in the last two years, describing the various predisposing conditions alongside the clinical manifestation, the diagnostic workup, and the treatment course. Moreover, we propose a brief literature review on Nocardia infections in the immunocompromised host, focusing on SOTRs and haematopoietic stem cell transplantation recipients and highlighting risk factors, clinical presentations, the diagnostic tools available, and current treatment and prophylaxis guidelines. Read More

View Article and Full-Text PDF

Advanced Molecular Characterisation in Relapsed and Refractory Paediatric Acute Leukaemia, the Key for Personalised Medicine.

J Pers Med 2022 May 27;12(6). Epub 2022 May 27.

Genetics Department (INGEMM), La Paz University Hospital, 28046 Madrid, Spain.

Relapsed and refractory (R/r) disease in paediatric acute leukaemia remains the first reason for treatment failure. Advances in molecular characterisation can ameliorate the identification of genetic biomarkers treatment strategies for this disease, especially in high-risk patients. The purpose of this study was to analyse a cohort of R/r children diagnosed with acute lymphoblastic (ALL) or myeloid (AML) leukaemia in order to offer them a targeted treatment if available. Read More

View Article and Full-Text PDF

Challenges in Cell Fate Acquisition to Scid-Repopulating Activity from Hemogenic Endothelium of hiPSCs Derived from AML Patients Using Forced Transcription Factor Expression.

Cells 2022 Jun 13;11(12). Epub 2022 Jun 13.

Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8N 3Z5, Canada.

The generation of human hematopoietic stem cells (HSCs) from human pluripotent stem cells (hPSCs) represents a major goal in regenerative medicine and is believed would follow principles of early development. HSCs arise from a type of endothelial cell called a "hemogenic endothelium" (HE), and human HSCs are experimentally detected by transplantation into SCID or other immune-deficient mouse recipients, termed SCID-Repopulating Cells (SRC). Recently, SRCs were detected by forced expression of seven transcription factors (TF) (ERG, HOXA5, HOXA9, HOXA10, LCOR, RUNX1, and SPI1) in hPSC-derived HE, suggesting these factors are deficient in hPSC differentiation to HEs required to generate HSCs. Read More

View Article and Full-Text PDF

Plays an Essential Role in the Survival and Maintenance of Hematopoietic Stem/Progenitor Cells.

Cells 2022 Jun 7;11(12). Epub 2022 Jun 7.

Center for Stem Cell Research and Application, Institute of Blood Transfusion, Chinese Academy of Medical Science & Peking Union Medical College (CAMS & PUMC), Chengdu 610025, China.

() gene encodes a protein named non-muscle heavy chain IIA (NMHC IIA), interacting with actin and participating in various biological processes. Mutations in cause an array of autosomal dominant disorders, known as -related diseases (-RD). However, the role of in normal hematopoiesis remains largely unexplored. Read More

View Article and Full-Text PDF

Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.

Cancers (Basel) 2022 Jun 13;14(12). Epub 2022 Jun 13.

Department of Pediatrics, CARTOX Program, Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Non-Hodgkin lymphoma (NHL) is a broad entity which comprises a number of different types of lymphomatous malignancies. In the pediatric and adolescent population, the type and prognosis of NHL varies by age and gender. In comparison to adults, pediatric and adolescent patients generally have better outcomes following treatment for primary NHL. Read More

View Article and Full-Text PDF

Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients.

Cancers (Basel) 2022 Jun 13;14(12). Epub 2022 Jun 13.

Department of Clinical Science, University of Bergen, 5020 Bergen, Norway.

Allogeneic stem cell transplantation is used in the treatment of high-risk hematological malignancies. However, this treatment is associated with severe treatment-related morbidity and mortality. The metabolic status of the recipient may be associated with the risk of development of transplant-associated complications such as graft-versus-host disease (GVHD). Read More

View Article and Full-Text PDF

High-Risk Acute Myeloid Leukemia: A Pediatric Prospective.

Biomedicines 2022 Jun 14;10(6). Epub 2022 Jun 14.

Unità Operativa di Trapianto di Cellule Staminali Ematopoietiche e Terapie Cellulari, Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon, 80123 Napoli, Italy.

Pediatric acute myeloid leukemia is a clonal disorder characterized by malignant transformation of the hematopoietic stem cell. The incidence and the outcome remain inferior when compared to pediatric ALL, although prognosis has improved in the last decades, with 80% overall survival rate reported in some studies. The standard therapeutic approach is a combined cytarabine and anthracycline-based regimen followed by consolidation with allogeneic stem cell transplantation (allo-SCT) for high-risk AML and allo-SCT for non-high-risk patients only in second complete remission after relapse. Read More

View Article and Full-Text PDF

Comparable clinical outcomes of haploidentical hematopoietic stem cell transplantation in patients with hepatitis-associated aplastic anemia and non-hepatitis-associated aplastic anemia.

Ann Hematol 2022 Jun 23. Epub 2022 Jun 23.

National Clinical Research Centre for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplant, Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.

Hepatitis-associated aplastic anemia (HAAA), a rare subtype of aplastic anemia (AA), is defined as bone marrow failure occurring after acute hepatitis. Severe HAAA requires immunosuppressive therapy (IST) or hematopoietic stem cell transplantation (HSCT) as lifesaving treatment. The outcomes of HAAA patients who underwent haploidentical hematopoietic stem cell transplantation (haplo-HSCT) have not been systematically evaluated. Read More

View Article and Full-Text PDF

Enrichment of cancer-predisposing germline variants in adult and pediatric patients with acute lymphoblastic leukemia.

Sci Rep 2022 Jun 23;12(1):10670. Epub 2022 Jun 23.

Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Despite recent progress in acute lymphoblastic leukemia (ALL) therapies, a significant subset of adult and pediatric ALL patients has a dismal prognosis. Better understanding of leukemogenesis and recognition of germline genetic changes may provide new tools for treating patients. Given that hematopoietic stem cell transplantation, often from a family member, is a major form of treatment in ALL, acknowledging the possibility of hereditary predisposition is of special importance. Read More

View Article and Full-Text PDF

C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma.

J Nucl Med 2022 Jun 23. Epub 2022 Jun 23.

Department of Nuclear Medicine, University Hospital Würzburg, Germany.

C-X-C motif chemokine receptor 4 (CXCR4)-targeted radioligand therapy (RLT) has already been applied to advanced blood cancers, such as multiple myeloma or diffuse large B-cell lymphoma. We herein present a series of patients with advanced T-cell lymphoma (TCL), who were scheduled for CXCR4-directed therapy as conditioning regimen, followed by hematopoietic stem cell transplantation (HSCT). Four patients with advanced, heavily pretreated and relapsed TCL (2 males, 2 females; median age, 50 years) without suitable alternative therapeutic options underwent CXCR4-directed PET and pretherapeutic dosimetry. Read More

View Article and Full-Text PDF

A national proficiency scheme for human leucocyte antigen typing by next-generation sequencing.

Clin Chim Acta 2022 Jun 20;533:85-88. Epub 2022 Jun 20.

National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/ National Center of Gerontology, PR China; Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, PR China; Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, PR China. Electronic address:

Background: Accurate human leucocyte antigen (HLA) typing is essential for solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). Next-generation sequencing (NGS) is increasingly adopted by clinical laboratories performing HLA typing. To ensure reliable NGS-based HLA typing throughout China, a HLA-NGS proficiency testing (PT) scheme was set up. Read More

View Article and Full-Text PDF

Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.

Int J Hematol 2022 Jun 23. Epub 2022 Jun 23.

Beijing Lu Daopei Institute of Hematology, Beijing, China.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for B-cell acute lymphoblastic leukemia (B-ALL). Although allo-HSCT can be curative for some B-ALL patients, relapse still occurs in some patients following allo-HSCT. Conventional chemotherapies show poor efficacy in B-ALL patients who have relapsed following allo-HSCT. Read More

View Article and Full-Text PDF

Romiplostim addition to conditioning prior to HSCT allows chemotherapy reduction while maintaining engraftment levels.

Blood Adv 2022 Jun 23. Epub 2022 Jun 23.

University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) offers are curative treatment approach for certain benign and malignant hematologic diseases. The actual HSCT is preceded by a conditioning therapy that reduces host-versus HSCT graft rejection and creates niche space for transplanted Hematopoietic Stem and Progenitor Cells (HSPCs). Conditioning consists of chemotherapy with or without irradiation and is a major cause of side-effects in HSCT. Read More

View Article and Full-Text PDF

Efficacy of hematopoietic stem cell transplantation in the treatment of children with non-severe aplastic anemia.

Pediatr Transplant 2022 Jun 23:e14340. Epub 2022 Jun 23.

Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.

Background: Non-severe aplastic anemia is more likely to develop into severe aplastic anemia, and there is no widely accepted treatment plan at present. Hematopoietic stem cell transplantation might be a new therapeutic strategy.

Methods: Retrospectively analyzed 32 patients with non-severe aplastic anemia who underwent hematopoietic stem cell transplantation from September 2007 to September 2020, and the 5-year estimated overall survival rate and the incidence of graft-versus-host disease were analyzed to evaluate the efficacy and safety of hematopoietic stem cell transplantation in the treatment of pediatric non-severe aplastic anemia. Read More

View Article and Full-Text PDF